News
Important Only
The Motley Fool12 hours ago
Compass Therapeutics Posts Wider Q2 Loss
Reuters12 hours ago
Kalvista Pharmaceuticals Announces Maintenance Of Orphan Designation For Sebetralstat In European Union
Reuters12 hours ago
Americas Gold Q2 revenue misses estimates on lower zinc, lead production and prices
Reuters12 hours ago
Compass Therapeutics Q2 net loss widens to $19.9 mln
Reuters12 hours ago
Biogen And Stoke Therapeutics Announce First Patient Dosed In Phase 3 Emperor Study Of Zorevunersen
Reuters12 hours ago
BinSentry Raises $50 Million to Modernize Animal Feed Supply Chains
Stocks
Compass Therapeutics Posts Wider Q2 Loss
Key PointsCompass Therapeutics posted a wider-than-expected GAAP loss per share of $(0.14) in the second quarter. as R&D spending climbed 47% to $16.4 million (GAAP) in the second quarter.No revenue was recorded, after $0.85 million (GAAP) in the prior-year period, reflecting the absence of licensin...The Motley Fool
12 hours ago
Commodities
Americas Gold Q2 revenue misses estimates on lower zinc, lead production and prices
OverviewAmericas Gold and Silver Q2 silver production up 36% yr/yrRevenue for Q2 falls 19%, missing analyst expectationsCo announces share consolidation and secures $100 mln loan facilityOutlookCompany expects commercial production at EC120 by end of 2025Company aims to leverage antimony as new reve...Reuters
12 hours ago
Other
Compass Therapeutics Q2 net loss widens to $19.9 mln
OverviewCompass Q2 net loss widens to $19.9 mln from $13.1 mln last yearCompany ends Q2 with $101 mln cash, runway into 2027Tovecimig shows fewer deaths than projected in Phase 2/3 studyOutlookCompany expects tovecimig secondary endpoint analysis in Q1 2026Compass plans CTX-8371 cohort expansions in...Reuters
12 hours ago
Other
Biogen And Stoke Therapeutics Announce First Patient Dosed In Phase 3 Emperor Study Of Zorevunersen
Aug 11 (Reuters) - Biogen Inc BIIB.O:BIOGEN AND STOKE THERAPEUTICS ANNOUNCE FIRST PATIENT DOSED IN PHASE 3 EMPEROR STUDY OF ZOREVUNERSEN, A POTENTIAL DISEASE-MODIFYING TREATMENT FOR DRAVET SYNDROMEReuters
12 hours ago
Other
Humacyte misses Q2 revenue estimates, net loss narrows
OverviewHumacyte Q2 revenue of $0.3 mln missed analyst expectations, per LSEG dataNet loss for Q2 narrows to $37.7 mln, but misses analyst estimates, per LSEG dataCo achieved significant progress in Symvess market launch with VAC and ECAT approvalsOutlookCompany plans to submit supplemental BLA in 2...Reuters
12 hours ago
Other
Harvard Bioscience Q2 revenue meet estimates
OverviewHarvard Bioscience Q2 2025 revenue in line with analyst expectations, per LSEG dataAdjusted EPS for Q2 meets analyst estimates, indicating stable performanceCompany signs credit amendment, extending refinance deadline to Dec 5, 2025OutlookHarvard Bioscience expects Q3 2025 revenue between $1...Reuters
12 hours ago
Other
Activist investor Engine Capital urges Avantor to refresh board with new directors
Aug 11 (Reuters) - Activist investor Engine Capital has urged life sciences firm Avantor's AVTR.N board to be refreshed with new directors, a letter on Monday showed.Engine Capital owns about 3% of the outstanding shares of Avantor.Reuters
12 hours ago
Other
Engine Capital Send Letter To Avantor Board to Improve Governance, Unlock Shareholder Value
Aug 11 (Reuters) - Avantor Inc AVTR.N:ENGINE CAPITAL SENDS LETTER TO AVANTOR’S BOARD OF DIRECTORS REGARDING OPPORTUNITIES TO IMPROVE GOVERNANCE AND UNLOCK SHAREHOLDER VALUEENGINE CAPITAL SAYS CLEAR AVANTOR BOARD NEEDS TO BE REFRESHED WITH NEW DIRECTORSENGINE CAPITAL: SEES PATH TO REALIZING 100% UPSI...Reuters
12 hours ago
Stocks
Europe Q2 earnings: Strong euro, tariff worries weigh but banks shine
Europe's Q2 earnings set to grow 3.1%Companies flag impact of strong euroBanks exhibit strong earnings growthConsumer-facing stocks facing higher costs, fragile demandBy Samuel Indyk and Danilo Masoni LONDON/MILAN, Aug 11 (Reuters) - European companies are proving they can just about endure U...Reuters
12 hours ago
Other
Kymera Therapeutics Q2 revenue misses expectations, net loss widens
OverviewKymera Q2 revenue misses analyst expectations, net income also missed, per LSEG dataCo remains well-capitalized with $1 bln cash, strategic partnership with GileadOutlookCompany has cash runway into second half of 2028Kymera's Gilead partnership could yield up to $750 mlnResult DriversGI...Reuters
12 hours ago
Other
Biorefining firm Green Plains' Q2 revenue falls, EPS misses estimates
OverviewGreen Plains Q2 2025 rev declines to $552.8 mln, missing analyst expectationsAdjusted EPS for Q2 misses consensus, reflecting non-cash charges and restructuring costsCo reports progress on carbon capture project, on track for Q4 start-upOutlookGreen Plains expects carbon sequestration to sta...Reuters
12 hours ago
